低氧反应性性结合剂触发了II型免疫细胞死亡,用于增强光动力免疫疗法
Maomao Ren1, Xin Sun1, Jiayi Lin1
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
概括
这项研究引入了A6-dMP-VP,这是一种新型结合物,通过光动力学疗法 (PDT) 有效诱导免疫细胞死亡 (ICD) 来增强抗瘤免疫疗法. 它克服了瘤微环境的挑战,抑制了原发性和转移性瘤.
科学领域:
- 生物医学工程 生物医学工程
- 癌症免疫疗法癌症免疫疗法
- 药物运输 药物运输 药物运输
背景情况:
- 光动力疗法 (PDT) 通过诱导免疫细胞死亡 (ICD) 在癌症免疫疗法中显示出潜力.
- PDT的临床应用受到低效的ICD诱导和免疫抑制性瘤微环境 (TME) 的限制.
研究的目的:
- 开发一种瘤向的,对低氧反应的酸-光敏感剂合物,用于增强抗瘤免疫疗法.
- 研究结合剂在诱导ICD和克服TME相关局限性的有效性.
主要方法:
- 合成A6-dMP-VP,一种结合物,结合了一种解性 (dMP),CD44向动机 (A6),低氧反应元素和脊髓 (VP).
- 在体外和体内对A6-dMP-VP的瘤积累,缺氧触发反应和ICD诱导机制 (II型ICD) 的评估.
- 评估免疫反应,包括树突细胞成熟和细胞毒性T细胞激活,以及对抗原和转移性瘤的抗瘤疗效.
主要成果:
- A6-dMP-VP在4T1瘤中表现出偏好的积累,并对低氧TME作出反应.
- 结合剂通过线粒体干扰和内质网膜应激有效诱导II型ICD,促进抗原的释放.
- 观察到树突细胞成熟和细胞毒性T细胞原始化的显著增强,导致主要和转移性瘤的强烈抑制.
结论:
- A6-dMP-VP是一种高效的II型ICD诱导剂,具有双重瘤治疗和PDT效应.
- 这种结合剂提供了一种有希望的策略,以克服PDT的局限性,并推进光动力学-瘤学免疫疗法.
- 开发的系统通过调节瘤微环境并增强抗瘤免疫力,为向癌症治疗提供了一种新的方法.
相关概念视频
01:27Tumor Immunotherapy
401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401
02:49Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
01:27Cytotoxic T Cells-mediated Immune Response
731
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
731